ATE249241T1 - Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung - Google Patents

Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung

Info

Publication number
ATE249241T1
ATE249241T1 AT98949847T AT98949847T ATE249241T1 AT E249241 T1 ATE249241 T1 AT E249241T1 AT 98949847 T AT98949847 T AT 98949847T AT 98949847 T AT98949847 T AT 98949847T AT E249241 T1 ATE249241 T1 AT E249241T1
Authority
AT
Austria
Prior art keywords
methods
mammals
nervous system
central nervous
nerve regeneration
Prior art date
Application number
AT98949847T
Other languages
English (en)
Inventor
John D Steeves
Jason K Dyer
Hans S Keirstead
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2219683 external-priority patent/CA2219683A1/en
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE249241T1 publication Critical patent/ATE249241T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT98949847T 1997-10-28 1998-10-28 Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung ATE249241T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2219683 CA2219683A1 (en) 1997-10-28 1997-10-28 Immunological composition and its method of use to transiently disrupt mammalian central nervous system myelin to promote neuronal regeneration
CA2251410 1998-10-16
PCT/CA1998/000997 WO1999021581A1 (en) 1997-10-28 1998-10-28 Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration

Publications (1)

Publication Number Publication Date
ATE249241T1 true ATE249241T1 (de) 2003-09-15

Family

ID=25679779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98949847T ATE249241T1 (de) 1997-10-28 1998-10-28 Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung

Country Status (11)

Country Link
US (2) US6969516B1 (de)
EP (1) EP1047449B1 (de)
JP (1) JP2001521008A (de)
AT (1) ATE249241T1 (de)
AU (1) AU748143B2 (de)
DE (1) DE69818106T2 (de)
DK (1) DK1047449T3 (de)
ES (1) ES2210829T3 (de)
IL (2) IL135799A0 (de)
PT (1) PT1047449E (de)
WO (1) WO1999021581A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002542299A (ja) * 1999-04-28 2002-12-10 ユニバーシティ・オブ・ブリティッシュ・コロンビア ミエリン特異性抗体および補体タンパク質を含むニューロン再生用組成物
GB0103174D0 (en) * 2001-02-08 2001-03-28 Smithkline Beecham Plc Novel method of treatment
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
GB0306309D0 (en) 2003-03-19 2003-04-23 Glaxo Group Ltd Method of treatment
EP2073898A1 (de) 2006-10-10 2009-07-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Komplementhemmung für verbesserte nervenregeneration
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
US10058471B2 (en) * 2014-02-21 2018-08-28 William M. Vaughan System and method of using hyperbaric oxygen therapy for treating concussive symptoms and musculoskeletal injuries and for pre-treatment to prevent damage from injuries
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
BR112019006781A2 (pt) 2016-10-07 2019-07-30 Novartis Ag receptores de antígeno quiméricos para o tratamento de câncer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6174490A (en) * 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
US6020140A (en) * 1991-08-09 2000-02-01 Washington University Autoantibodies and their targets in the diagnosis of peripheral neuropathies
HU217543B (hu) * 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US5714385A (en) * 1995-05-10 1998-02-03 Genentech, Inc. Media for culturing schwann cells
US6228598B1 (en) * 1998-10-02 2001-05-08 Washington University Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies

Also Published As

Publication number Publication date
JP2001521008A (ja) 2001-11-06
EP1047449B1 (de) 2003-09-10
DE69818106D1 (de) 2003-10-16
EP1047449A1 (de) 2000-11-02
IL135799A (en) 2011-01-31
AU748143B2 (en) 2002-05-30
AU9617998A (en) 1999-05-17
IL135799A0 (en) 2001-05-20
PT1047449E (pt) 2004-04-30
WO1999021581A1 (en) 1999-05-06
ES2210829T3 (es) 2004-07-01
US6969516B1 (en) 2005-11-29
DE69818106T2 (de) 2004-06-17
US6548061B1 (en) 2003-04-15
DK1047449T3 (da) 2004-01-26

Similar Documents

Publication Publication Date Title
Narayanan et al. Biosynthesis and regulation of type V collagen in diploid human fibroblasts.
ATE249241T1 (de) Immunologische zusammensetzungen und verfahren zur transienten änderung des zentralnervensystem- myelins der saügetiere und förderung der nerven- regenerierung
Vaghy et al. Identification of a novel 1, 4-dihydropyridine-and phenylalkylamine-binding polypeptide in calcium channel preparations.
Barnes et al. The collagen-platelet interaction
Vaughan et al. Proteoglycan Lt from chicken embryo sternum identified as type IX collagen.
ATE137802T1 (de) Monoklonaler antikörper, der mit einer neuen hla- determinante auf mhc-klasse-i-moleküle reagiert, und verfahren zur aktivierung von lymphozyten
KR910001057A (ko) 이중특이성 및 올리고특이성 일가 및 올리고가 수용체. 이의 제조방법 및 이의 용도
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
DE60031419D1 (de) Zusammensetzungen und verfahren für verbesserte zellkultur
CY1107821T1 (el) Πολυπεπτιδιο παραγοντα viii με ενεργοτητα παραγοντα viii:c
DE68915675D1 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
ATE171042T1 (de) Verfahren und zusammensetzungen zur verbesserung der symptome von sepsis
ATE151113T1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
NL300372I1 (nl) Hybride immunoglobulinen voor gebruik bij therapeutische werkwijzen
ATE403001T1 (de) Antigenbindungsfragmente die spezifisch krebszellen nachweisen, nukleotide die für diese fragmente kodieren, und deren verwendung zur vorbeugung und zum nachweis von krebs
MX7235E (es) Procedimiento para preparar una solucion inyectable intravenosamente de globulina de suero inmune
NO166943C (no) Analogifremgangsmaate for fremstilling av enzymresistente immunomodulerende peptider.
DE69939312D1 (de) Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen
DE3674642D1 (de) Zur modifizierung von bitumen verwendbare polymerzusammensetzungen und so modifizierte bitumenmassen.
DK407488A (da) Fremgangsmaade til behandling af overskud af jern
Corces et al. Binding of microtubule proteins to DNA: specificity of the interaction
Kotani et al. Characterization of microtubule‐associated proteins isolated from bovine adrenal gland
ATE136608T1 (de) Verfahren zur herstellung von mischgut für strassendecken mittels zweifacher beschichtung
DE3689177D1 (de) Verfahren zur Behandlung von Füllmaterialien und zur Konstruktion rutschfester Strassenoberflächen.
Crofton Site of alkaline phosphatase attachment in alkaline phosphatase-immunoglobulin G complexes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1047449

Country of ref document: EP

REN Ceased due to non-payment of the annual fee